600276.SS
Jiangsu Hengrui Medicine Co., Ltd.
1W: -4.9%
1M: -6.7%
3M: -12.5%
YTD: -7.4%
1Y: +21.6%
3Y: +47.7%
5Y: -24.5%
¥51.63 ($7.48)
-2.47 (-4.57%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap¥345.1B ($50.0B)
52W Range44.2-74.04
Volume41,152,562
Avg Volume48,917,382
Beta0.21
Dividend¥0.20
Analyst Ratings
No analyst coverage
Company Info
CEOPiao Yang Sun
Employees20,238
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date2000-10-18
Websitehrs.com.cn
38 Huanghe Rd Eco & Tech Dev Park
Lianyungang 222000
CN
Lianyungang 222000
CN
86 518 8122 0983
About Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Latest News
No recent news
Recent Insider Trades
No insider trades found